CCR8 and neoplasm: Among these, CCR8 emerged as a particularly promising therapeutic target due to its strong correlation with immune checkpoint molecules and genomic instability markers such as tumor mutational burden (TMB) and microsatellite instability (MSI) (45), suggesting its potential as a mechanistic link between Treg-driven immunosuppression and ICI resistance (46).